- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | OS Therapies: OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma | 374 | Newsfile | Received notice for upcoming USDA meetingCompany is reviewing strategic alternatives to monetize OS Animal Health ("OSAH")Grasonville, Maryland--(Newsfile Corp. - October 7, 2026) - OS Therapies, Inc.... ► Artikel lesen | |
| Di | OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment | 1 | Benzinga.com | ||
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| Di | OS Therapies: OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial | 435 | Newsfile | Leading Clinical Stage Oncology Company Releases Significant Findings from OST-HER2-Treated Patients72.7 percent three-year overall survival vs. 45.8 percent comparable combined historical control (p... ► Artikel lesen | |
| Mo | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 01.10. | OS Therapies appoints Kerry Clem as CCO, Frank Knuettel II as CFO | 2 | Seeking Alpha | ||
| 01.10. | OS Therapies: OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer | 417 | Newsfile | Experienced biotech leaders to focus on preparations for U.S., U.K., and European commercial launch of the Company's lead product candidate Herlystic(OST-HER2; daznelimgene lisbac)Grasonville, Maryland--(Newsfile... ► Artikel lesen | |
| 24.09. | OS Therapies: OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac) | 448 | Newsfile | New York, New York and Rockville, Maryland--(Newsfile Corp. - September 24, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based... ► Artikel lesen | |
| 21.09. | OS Therapies: OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis | 598 | Newsfile | Recent U.K. MHRA Scientific Advice Meeting (SAM) that resulted in full alignment to initiate confirmatory Phase 3 trial in U.K. with existing Phase 2 drug product paved the way Conditional Marketing... ► Artikel lesen | |
| 17.09. | OS Therapies: OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program | 576 | Newsfile | FDA aligns with MHRA and EMA on adaptive design for Phase 3 trialAfter successful Scientific Advice Meeting, Company accepts MHRA request to become he Company's' sponsor into Project Orbis to harmonize... ► Artikel lesen | |
| 15.09. | OS Therapies: OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing | 463 | Newsfile | Overall Survival (OS) historical-control data gains HMRA and EMA support for pending CMAA submissionsFull alignment achieved on confirmatory Phase 3 trial designComplete CMAA submission expected in... ► Artikel lesen | |
| 09.09. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | OS Therapies Reports Strong Survival Data for Bone Cancer Treatment | 1 | Benzinga.com | ||
| 08.09. | OS Therapies: OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial | 420 | Newsfile | 71.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical control (p = 0.002)The two remaining patients who have not yet reached the 3-year timepoint from... ► Artikel lesen | |
| 02.09. | OS Therapies: OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance | 789 | Newsfile | Management will participate at Jefferies Global Healthcare Conference, H.C. Wainwright Global Investment Conference, ROTH Healthcare Opportunities Conference Management and business development advisors... ► Artikel lesen | |
| 21.08. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | OS Therapies Secures Up To $10 Million Debt Financing Against U.K. Tax Refunds And R&D Credits | 1 | pulse2.com | ||
| 17.08. | OS Therapies GAAP EPS of -$0.20 misses by $0.03 | 1 | Seeking Alpha | ||
| 17.08. | OS Therapies: OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates | 1.006 | Newsfile | Up to $10 million debt financing supported by U.K. subsidiary VAT refunds and reimbursable R&D tax credits, including $5 million funded at the August 10, 2026 first closingFDA Type C Statistical... ► Artikel lesen | |
| 14.08. | OS Therapies Inc - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.08. | OS Therapies: OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma | 717 | Newsfile | Meeting to occur in mid-September 2026Interim 3-year Overall Survival data expected early September, 2026Decisions on appropriate comparator arm to interpret OST-HER2 clinical efficacy, RMAT designation... ► Artikel lesen |
1 2 3 4 Weiter >>
69 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,583 | +2,62 % | Valneva: Großbritannien entzieht Chikungunya-Impfstoff die Zulassung | Valneva verliert in Großbritannien die Marktzulassung für seinen Chikungunya-Impfstoff IXCHIQ. Die britische Arzneimittelbehörde MHRA hat die Genehmigung nach einer erneuten Nutzen-Risiko-Bewertung... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 45,835 | +1,95 % | CRISPR Therapeutics AG: CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026 | ||
| PALATIN TECHNOLOGIES | 8,940 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| OCUGEN | 0,906 | +3,42 % | Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate | European Affiliate, based in Amsterdam, to support upcoming marketing authorization submissions, OCU410 Phase 3 development program, and potential commercialization in Europe MALVERN, Pa., Oct. 06... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,040 | 0,00 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,920 | -2,09 % | Jim Cramer Explains His Hesitation Over Sarepta (SRPT) Therapeutics | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,123 | +3,71 % | Pacific Biosciences Collaborates With TychoBio For AI-powered RNA Data Creation; Shares Up | ||
| REDHILL BIOPHARMA | 0,575 | -0,61 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| IMMUNIC | 6,802 | +1,07 % | EQS-News: Immunic AG: Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 0,990 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026 | Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www.VirtualInvestorConference.comKing of Prussia, Pennsylvania--(Newsfile Corp. - October 6... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,600 | -1,49 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights | Ocular's AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence... ► Artikel lesen | |
| VERASTEM | 6,982 | -3,51 % | Verastem stock maintained at Buy by BTIG ahead of data readout | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,522 | +6,50 % | IP Group sells down stake in Oxford Nanopore | ||
| VOYAGER THERAPEUTICS | 2,118 | +0,38 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,430 | +3,85 % | Rocket Pharma upgraded at Goldman Sachs on Danon disease therapy |
OS THERAPIES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,630 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.